Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Neoplasms 13Lymphoma 8Lymphoma, Non-Hodgkin 7Recurrence 4Solid Tumor 3Melanoma 3Lymphoma, Large-Cell, Anaplastic 3Advanced Solid Tumors 3Solid Tumors 2Hodgkin Disease 2Hematologic Neoplasms 2Hematologic Diseases 2Carcinoma, Non-Small-Cell Lung 2Solid Tumours 1Solid Tumor, Adult 1Sarcoma, Synovial 1Sarcoma 1Rhabdoid Tumor 1Prostatic Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Mesothelioma 1Malignancies Multiple 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Colorectal Neoplasms 1Carcinoma 1Advanced Solid Tumours 1Advanced Solid Tumor 1Advanced Solid Neoplasm 1

Interventions

Dexamethasone 808Bortezomib 446Lenalidomide 430Cyclophosphamide 336Melphalan 250Calcium Dobesilate 236daratumumab 217pomalidomide 201carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67Prednisone 64dexamethasone 21-phosphate 63isatuximab 62elotuzumab 60auricularum 57Antilymphocyte Serum 55belantamab mafodotin 54Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × Rifampin × Clear all
NCT00608907 2012-01-30

An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)

Millennium Pharmaceuticals, Inc.

Phase 1 Completed
61 enrolled 9 charts
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡